Trade NBIX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Neurocrine Biosciences, Inc. (NBIX) is trading at US$154.98, down 0.61% today as of Aug 28, 10:27 EDT. The company has a market capitalisation of US$15.51B. Over the past 52 weeks, NBIX has traded between US$122.14 and US$186.12. On Syfe you can trade NBIX with $0 commission and add it to your watchlist.
| Previous close | US$155.92 |
|---|---|
| Market cap | US$15.51B |
| P/E ratio | 17.56 |
| 52-week range | US$122.14 – US$186.12 |
| Volume | 730.17K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Year: 1996
Neurocrine Biosciences, Inc. (NBIX) stock is trading at US$154.98, -0.61% from the previous close of US$155.92.
The market cap for Neurocrine Biosciences, Inc. (NBIX) stock is approximately US$15.51B.
The price-to-earnings ratio for Neurocrine Biosciences, Inc. (NBIX) is 17.56, based on the latest reported earnings.
The 52-week high for Neurocrine Biosciences, Inc. (NBIX) stock is US$186.12.
The 52-week low for Neurocrine Biosciences, Inc. (NBIX) stock is US$122.14.
Neurocrine Biosciences, Inc. (NBIX) does not currently pay a dividend.
Stay on top of NBIX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
